Table 2. Demographic and clinical characteristics of ART-experienced and -naïve HIV-1-infected patients ≧15 years old (n = 90).
| Characteristic | ART-experienced, n = 31 | ART-naïve, n = 59 | P | |
| Age, years | Median (IQR) | 38 (35–43) | 42 (32–49) | 0.251 |
| Sex (%) | Female | 18 (58.1) | 38 (64.4) | 0.649 |
| Male | 13 (41.9) | 21 (35.6) | ||
| Risk factor for HIV infection (%) | Heterosexual contact | 31 (100.0) | 57 (96.6) | 0.543 |
| Transfusion | 0 (0.0) | 2 (3.4) | ||
| HIV serology (%)a | HIV-1 positive | 29 (93.5) | 59 (100.0) | 0.116 |
| HIV-1 and -2 positive | 2 (6.5) | 0 (0.0) | ||
| CD4+ T-cell count, cells/µl | Median (IQR) | 230 (87–376) | 237 (86–426) | 0.750 |
| HIV-1 viral load, log10 copies/ml | Median (IQR) | 3.7 (3.3–4.1) | 4.4 (3.7–5.0) | 0.006 |
| HIV-1 genotype (%) | CFR02_AG | 18 (58.1) | 42 (71.2) | 0.638 |
| A3 | 2 (6.5) | 2 (3.4) | ||
| CRF06_cpx | 1 (3.2) | 1 (1.7) | ||
| CRF09_cpx | 1 (3.2) | 1 (1.7) | ||
| URF | 9 (29.0) | 13 (22.0) | ||
| ART regimen (%) | − | |||
| First line | d4T+3TC+EFV | 10 (32.3) | − | |
| AZT+3TC+NVP | 10 (32.3) | − | ||
| AZT+3TC+EFV | 7 (22.6) | − | ||
| d4T+3TC+NVP | 3 (9.7) | − | ||
| Second line | AZT+3TC+NFV | 1 (3.2) | − | |
| Duration of ART, months | Median (IQR) | 16.1 (6.8–30.3) | − | − |
| Adherence (%)b | Good | 17 (54.8) | − | − |
| Satisfactory | 8 (25.8) | − | ||
| Poor | 6 (19.4) | − | ||
ART, antiretroviral therapy; AZT, zidovudine; CRF, circulating recombinant form; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NFV, nelfinavir; NVP, nevirapine; 3TC, lamivudine; and URF, unique recombinant form.
a
HIV serology was determined using New LAV Blot I and II (Bio-Rad Laboratories, Marnes-la-Coquette, France).
b
Good, 100% pills taken; Satisfactory, ≧95%, but <100% pills taken; Poor, <95% pills taken.